Showing 7431-7440 of 9758 results for "".
- Changes Afoot at Valeant Pharmaceuticalshttps://practicaldermatology.com/news/changes-afoot-at-valeant-pharmaceuticals/2458527/Amid reports that its Obagi Medical Products and Solta Medical units are on the block, Valeant Pharmaceuticals is assuring investors that the company is focused on the future and has plans to fix its dermatology unit. Valeant CEO Joseph Papa cite
- Acne Scars: Survey Highlights the Negative Ways Acne and Acne Scars Can Affect Confidencehttps://practicaldermatology.com/news/acne-scars-survey-highlights-the-negative-ways-acne-and-acne-scars-can-affect-quality-of-life/2458539/Ninety-nine percent people would have more confidence if their acne and acne scars were gone, according to a new survey for Suneva Medical. When it comes to skin issues, respondents feel that acne scars are worse than having acne, eczema or rosacea. Nearly half of adults still have
- Dermira's DRM04 Shows Promise for Primary Axillary Hyperhidrosishttps://practicaldermatology.com/news/dermiras-drm04-shows-promise-for-primary-axillary-hyperhidrosis/2458543/Dermira’s DRM04 may help put the brakes on primary axillary hyperhidrosis, according to topline results from two Phase 3 trials. Based on the results of these trials, Dermira plans to submit a New Drug Application to the US Food and Drug Administ
- Pfizer/Anacor Merger To Fuel Already Robust AD Pipelinehttps://practicaldermatology.com/news/pfizeranacor-merger-fuels-already-robust-ad-pipeline/2458542/For years, there were few, if any, promising new treatments for atopic dermatitis (AD), but today the pipeline is robust, and a Pfizer-Anacor merger may help both of the companies’ pipeline candidates gain market share,
- Allergan's TEFLARO® OK'd for Pediatric Patientshttps://practicaldermatology.com/news/allergans-teflaro-oked-for-pediatric-patients/2458547/Allergan’s TEFLARO® (ceftaroline fosamil) is now indicated for pediatric patients, making it the first branded IV antibiotic approved for this population in more than a decade. The U.S. Food and Drug Administration (FDA) appr
- FDA Accepts Allergan's NDA Filing for Oxymetazoline HCI Cream 1.0% for Facial Erythemahttps://practicaldermatology.com/news/fda-accepts-allergans-nda-filing-for-oxymetazoline-hci-cream-10/2458553/The FDA accepted Allergan plc's New Drug Application (NDA) filing for oxymetazoline HCl cream 1.0%, an investigational topical prescription product for the treatment of persistent facial erythema (redness) associated with rosacea in adults. Allergan expects the Prescription Drug User Fee
- Cynosure Receives FDA Clearance to Market PicoSure Energy Delivery System for Tattoos and Pigmented Lesionshttps://practicaldermatology.com/news/cynosure-receives-fda-clearance-to-market-picosure-energy-delivery-system-for-tattoos-and-pigmented-lesions/2458554/The FDA granted clearance to Cynosure to market a new Laser Delivery System for PicoSure. Together with the FDA cleared 532nm and 755nm wavelengths, Cynosure's new 1064nm Laser Delivery System improves the multi-wavelength laser technology for removing the full color spectrum of tattoo inks i
- Novel Topical AD Drug Shows Promise in Phase 2 Studyhttps://practicaldermatology.com/news/novel-ad-drug-shows-promise-in-phase-2-study/2458555/Medimetriks’ MM36 (previously known as OPA-15406) performed well in a Phase 2 trial for the treatment of mild-to-moderate atopic dermatitis, a new study in in Journal of the American Academy of Dermatology shows. The investigational t
- Congrats: Dr. Barbara Gilchrest Receives the 24th David Martin Carter Mentor Awardhttps://practicaldermatology.com/news/congrats-dr-barbara-gilchrest-receives-the-24th-david-martin-carter-mentor-award/2458556/Barbara A. Gilchrest, MD of Harvard Medical School and Massachusetts General Hospital in Boston received the David Martin Carter Mentor Award at the Annual Meeting of the Society for Investigative Dermatology in Scottsdale, Ariz. Dr. Gilchrest plus the recipients of The Researc
- Feet Get Skin Cancer Too, ACFAS Warnshttps://practicaldermatology.com/news/feet-get-skin-cancer-too-acfas-warns/2458565/Skin cancer of the foot is prevalent and can be fatal if not caught early, the American College of Foot and Ankle Surgeons (ACFAS) warns. While all types of skin cancer, including squamous cell and basal cell carcinoma, can be found